Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

571

Participants

Timeline

Start Date

May 17, 2013

Primary Completion Date

January 24, 2016

Study Completion Date

April 24, 2025

Conditions
Unresectable Pleural or Peritoneal Malignant Mesothelioma
Interventions
DRUG

Tremelimumab

Tremelimumab is to be administered as an IV solution, followed by observation.

DRUG

Placebo

Placebo is to be administered as an IV solution, followed by observation.

Trial Locations (104)

2045

Research Site, Törökbálint

2065

Research Site, Saint Leonards

2100

Research Site, Copenhagen

2250

Research Site, Gosford

2298

Research Site, Waratah

2650

Research Site, Edegem

3000

Research Site, Leuven

3084

Research Site, Heidelberg

3128

Research Site, Box Hill

3165

Research Site, East Bentleigh

3200

Research Site, Gyöngyös - Mátraháza

4032

Research Site, Chermside

4066

Research Site, Auchenflower

5000

Research Site, Adelaide

6009

Research Site, Nedlands

7570

Research Site, Kraaifontein

9000

Research Site, Ghent

10043

Research Site, Orbassano

10060

Research Site, Candiolo

10065

Research Site, New York

13125

Research Site, Berlin

14076

Research Site, Caen

14642

Research Site, Rochester

15100

Research Site, Alessandria

16132

Research Site, Genova

19104

Research Site, Philadelphia

19718

Research Site, Newark

20014

Research Site, Donostia / San Sebastian

20089

Research Site, Rozzano

20133

Research Site, Milan

21075

Research Site, Hamburg

21201

Research Site, Baltimore

21231

Research Site, Baltimore

22185

Research Site, Lund

22927

Research Site, Großhansdorf

23538

Research Site, Lübeck

24125

Research Site, Bergamo

27710

Research Site, Durham

28040

Research Site, Madrid

30912

Research Site, Augusta

31059

Research Site, Toulouse

33081

Research Site, Aviano

33612

Research Site, Tampa

35033

Research Site, Rennes

35128

Research Site, Padua

40138

Research Site, Bologna

41013

Research Site, Seville

44710

Research Site, Canton

47014

Research Site, Meldola

53100

Research Site, Siena

55445

Research Site, Minneapolis

58128

Research Site, Jeonnam

58185

Research Site, Linköping

58675

Research Site, Hemer

59037

Research Site, Lille

60637

Research Site, Chicago

61615

Research Site, Peoria

72037

Research Site, Le Mans

73730

Research Site, Esslingen a.N.

74245

Research Site, Löwenstein

75390

Research Site, Dallas

76137

Research Site, Karlsruhe

77030

Research Site, Houston

79106

Research Site, Freiburg im Breisgau

82131

Research Site, Gauting

84101

Research Site, Beersheba

85259

Research Site, Scottsdale

90025

Research Site, Los Angeles

90404

Research Site, Santa Monica

92093

Research Site, La Jolla

94143

Research Site, San Francisco

94805

Research Site, Villejuif

115478

Research Site, Moscow

197022

Research Site, Saint Petersburg

200385

Research Site, Craiova

603006

Research Site, Nizhny Novgorod

06511

Research Site, New Haven

M5G 2M9

Research Site, Toronto

G1V 4G5

Research Site, Sainte-Foy

06189

Research Site, Nice

4818 CK

Research Site, Breda

5623EJ

Research Site, Eindhoven

3015 GD

Research Site, Rotterdam

80-952

Research Site, Gdansk

60-693

Research Site, Poznan

70-891

Research Site, Szczecin

02-781

Research Site, Warsaw

0081

Research Site, Pretoria

0181

Research Site, Pretoria

03722

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

08035

Research Site, Barcelona

08208

Research Site, Sabadell (Barcelona)

SE90185

Research Site, Umeå

LS9 7TF

Research Site, Leeds

LE1 5WW

Research Site, Leicester

EC1A 7BE

Research Site, London

SE1 9RT

Research Site, London

ME16 9QQ

Research Site, Maidstone

M23 9LT

Research Site, Manchester

CH63 4JY

Research Site, Metropolitan Borough of Wirral

PL6 8DH

Research Site, Plymouth

SO16 6YD

Research Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY

NCT01843374 - Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma | Biotech Hunter | Biotech Hunter